Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms
- 1 December 2006
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in HIV and AIDS
- Vol. 5 (6), 584-593
- https://doi.org/10.1097/01.moh.0000239710.47921.d2
Abstract
The antiphospholipid syndrome is a disorder of recurrent thrombosis, pregnancy loss and thrombocytopenia associated with the presence of antiphospholipid antibodies and persistently positive anticardiolipin or lupus anticoagulant positive tests. Since its recognition in the 1980s, growing interest in the field, not only with respect to diagnosis and treatment, but also regarding the pathogenesis of antiphospholipid antibodies, has emerged. First, this review addresses the recently updated classification criteria for diagnosis and treatment of the antiphospholipid syndrome. A discussion on the newly described potential beneficial roles of hydroxychloroquine and the statins for the treatment of antiphospholipid syndrome-associated clinical manifestations is included. Importantly, this article analyzes recent data that examine the molecular and intracellular events that antiphospholipid antibodies trigger in target cells, as well as new findings in the identification of the receptors for these antibodies on the membrane of those cells. A separate section discusses novel pathogenic mechanisms of antiphospholipid antibodies, including the activation of complement and their interaction with homologous catalytic domains of several serine proteases of the coagulation system. Understanding the molecular interactions and the intracellular signaling that antiphospholipid antibodies trigger, new therapeutic and targeted strategies to ameliorate clinical manifestations in patients with antiphospholipid syndrome may be established.Keywords
This publication has 78 references indexed in Scilit:
- Telomere loss, senescence, and genetic instability in CD4+ T lymphocytes overexpressing hTERTBlood, 2005
- Involvement of p38 MAPK in the up‐regulation of tissue factor on endothelial cells by antiphospholipid antibodiesArthritis & Rheumatism, 2005
- Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazepBlood, 2004
- Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombinArthritis & Rheumatism, 2004
- Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemiaBlood, 2003
- An IgG antiprothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation timesArthritis & Rheumatism, 1999
- Characterization of IgG monoclonal anti‐cardiolipin/anti‐β2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodiesBritish Journal of Haematology, 1999
- Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosusLupus, 1996
- A comparison of cardiac valvular involvement in the primary antiphospholipid syndrome versus anticardiolipin-negative systemic lupus erythematosusAmerican Heart Journal, 1993
- SYNDROME OF THE BLACK SWANRheumatology, 1987